RPG Life Sciences Q4 FY26 Revenue up 23.6%, Recommends 300% Dividend
RPG Life Sciences reported strong financial results for Q4 FY26 and the full fiscal year. For Q4 FY26, revenue from operations increased by 23.6% year-on-year to ₹176.9 crores, with an EBITDA margin of 25.6%. The Domestic Formulation (DF) business grew robustly by 18.2%, outperforming the Indian Pharma Market by 1.8 times. The API division saw a significant comeback, growing 144.3% in Q4 after its unit resumed operations post-fire. For the full FY26, revenue grew 8.3% to ₹707.5 crores, maintaining a healthy EBITDA margin of 24.4%. The DF business, contributing 70% of sales, delivered 13.7% growth, driven by strong performance in key therapy baskets. The Board recommended a final dividend of ₹24 per equity share (300%) for FY26. The company plans to strengthen its product pipeline, brand equity, and global footprint.
Key Highlights
- Q4 FY26 revenue grew 23.6% YoY to ₹176.9 crores, with 25.6% EBITDA margin.
- FY26 revenue increased 8.3% to ₹707.5 crores, achieving 24.4% EBITDA margin.
- Domestic Formulations (DF) business outperformed market, growing 18.2% in Q4.
- API division registered 144.3% growth in Q4 after unit resumed operations.
- Board recommended a final dividend of ₹24 per share (300%) for FY26.